Crescita Therapeutics Inc (CTX)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Crescita Therapeutics Inc (CTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013134
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月27日
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Crescita Therapeutics Inc (Crescita Therapeutics) develops products for the treatment of skin diseases and their symptoms. The company’s product portfolio includes over-the-counter and prescription products such as topical creams. It offers pliaglis, a local anesthetic cream for superficial dermatological and cosmetic procedures. Crescita Therapeutics along with Ferndale Laboratories, Inc. develops Mical (1) and Mical (2) for the therapeutic areas of psoriasis and dermatological skin treatment, respectively. Mical (1) is in Phase 1 clinical trials and and Mical (2) is in preclinical stage of development. The company develops products using drug delivery platform that include multiplexed molecular penetration enhancers (MMPE) and DuraPeel. Crescita Therapeutics is headquartered in Mississauga, Ontario, Canada.

Crescita Therapeutics Inc (CTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
INTEGA Skin Sciences Acquires Alyria Skincare Product Line from Sanofi Consumer Health for USD1.3 Million 10
Licensing Agreements 11
Taro Pharma Enters into Licensing Agreement with Crescita Therapeutics 11
Dermatological Contract Research Company Enters into Licensing Agreement with Crescita Therapeutics 12
Knight Therapeutics Enters into Licensing Agreement with INTEGA Skin Sciences 13
Debt Offering 14
Crescita Therapeutics Raises USD0.7 Million in Private Placement of 9% Convertible Debenture 14
Asset Transactions 15
Crescita Therapeutics Divests Manufacturing Facility in Germany 15
Acquisition 16
Knight Therapeutics Acquires 4% Stake in Crescita Therapeutics 16
Crescita Therapeutics Acquires Intega Skin Sciences for USD7.6 Million 17
Crescita Therapeutics Inc – Key Competitors 18
Crescita Therapeutics Inc – Key Employees 19
Crescita Therapeutics Inc – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Financial Announcements 21
Nov 10, 2017: Crescita Therapeutics Announces 2017 Third Quarter Results and Appoints New CFO 21
Aug 14, 2017: Crescita Therapeutics Announces Profitable 2017 Second Quarter Results 23
May 15, 2017: Crescita Therapeutics Announces 2017 First Quarter Results 25
Mar 30, 2017: Crescita Therapeutics Announces 2016 Fourth Quarter and Year-End Results 27
Nov 14, 2016: Crescita Therapeutics Announces 2016 Third Quarter Results 29
Jul 27, 2016: Crescita Therapeutics Announces 2016 Second Quarter Results 30
May 10, 2016: Crescita Therapeutics Announces 2016 First Quarter Results 32
Corporate Communications 34
Apr 12, 2017: Crescita Therapeutics Announces the Appointment of a New President 34
Feb 10, 2017: Crescita Therapeutics Announces Management and Board Changes 35
Nov 03, 2016: Crescita Appoints Dan Chicoine as Interim CEO 36
Sep 29, 2016: Crescita Therapeutics Announces Changes to the Board of Directors 37
Product News 38
Jan 26, 2017: Crescita Therapeutics Announces Launch of ISDIN Product Line at Brunet Pharmacy 38
Other Significant Developments 39
Mar 07, 2016: Crescita Therapeutics Provides Corporate Update 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Crescita Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
INTEGA Skin Sciences Acquires Alyria Skincare Product Line from Sanofi Consumer Health for USD1.3 Million 10
Taro Pharma Enters into Licensing Agreement with Crescita Therapeutics 11
Dermatological Contract Research Company Enters into Licensing Agreement with Crescita Therapeutics 12
Knight Therapeutics Enters into Licensing Agreement with INTEGA Skin Sciences 13
Crescita Therapeutics Raises USD0.7 Million in Private Placement of 9% Convertible Debenture 14
Crescita Therapeutics Divests Manufacturing Facility in Germany 15
Knight Therapeutics Acquires 4% Stake in Crescita Therapeutics 16
Crescita Therapeutics Acquires Intega Skin Sciences for USD7.6 Million 17
Crescita Therapeutics Inc, Key Competitors 18
Crescita Therapeutics Inc, Key Employees 19
Crescita Therapeutics Inc, Subsidiaries 20

★海外企業調査レポート[Crescita Therapeutics Inc (CTX)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sudarshan Chemical Industries Ltd (SUDARSCHEM):企業の財務・戦略的SWOT分析
    Sudarshan Chemical Industries Ltd (SUDARSCHEM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • Innergex Renewable Energy Inc (INE):企業の財務・戦略的SWOT分析
    Innergex Renewable Energy Inc (INE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • TIBCO Software, Inc.:企業の戦略・SWOT・財務分析
    TIBCO Software, Inc. - Strategy, SWOT and Corporate Finance Report Summary TIBCO Software, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • White Mountains Insurance Group Ltd:企業のM&A・事業提携・投資動向
    White Mountains Insurance Group Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's White Mountains Insurance Group Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on …
  • Firstec Co., Ltd.:企業の戦略・SWOT・財務分析
    Firstec Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Firstec Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Eguana Technologies Inc. (EGT):企業の財務・戦略的SWOT分析
    Eguana Technologies Inc. (EGT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Gerdau S.A.:企業の戦略・SWOT・財務分析
    Gerdau S.A. - Strategy, SWOT and Corporate Finance Report Summary Gerdau S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Kemwell Biopharma Pvt Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Kemwell Biopharma Pvt Ltd (Kemwell) formerly Kemwell Pvt Ltd, a subsidiary of Recipharm AB is a healthcare solutions provider that offers product development and manufacturing solutions. The organization provides contract pharmaceutical development and manufacturing organization and concentr …
  • Mayo Foundation for Medical Education and Research:企業の戦略的SWOT分析
    Mayo Foundation for Medical Education and Research - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key compet …
  • International Drug Development Institute-製薬・医療分野:企業M&A・提携分析
    Summary International Drug Development Institute (IDDI) is a healthcare institute that offers clinical data collection, analysis, trial design and trial reporting services. The institute offers biostatistical services and eClinical services and risk-based monitoring programs. Its biostatistical and …
  • Everist Genomics Inc-医療機器分野:企業M&A・提携分析
    Summary Everist Genomics Inc (Everest Health), formerly Genetics Squared Inc is a developer of prognostics, medical diagnostic and therapeutic selection technologies. The company provides angiodefender cardiovascular disease diagnostic system, a non invasive device that is used for combining sensor …
  • OGK-2 (OGKB):企業の財務・戦略的SWOT分析
    OGK-2 (OGKB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pote …
  • Sensus Healthcare Inc (SRTS):医療機器:M&Aディール及び事業提携情報
    Summary Sensus Healthcare Inc (Sensus) designs, manufactures and markets proprietary medical devices for the treatment of various types of cancers and skin diseases. The company offers superficial radiation therapy (SRT) technology based non-surgical treatment options for patients suffering from var …
  • Sigla, S.A.:企業の戦略的SWOT分析
    Sigla, S.A. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Kennametal Inc (KMT):企業の財務・戦略的SWOT分析
    Kennametal Inc (KMT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Takasago International Corporation (4914):企業の財務・戦略的SWOT分析
    Takasago International Corporation (4914) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Fuller, Smith & Turner Plc:企業の戦略・SWOT・財務情報
    Fuller, Smith & Turner Plc - Strategy, SWOT and Corporate Finance Report Summary Fuller, Smith & Turner Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Toronto Hydro Corp:企業の戦略的SWOT分析
    Toronto Hydro Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Royal Dutch Shell Plc (RDSA)-石油・ガス分野:企業M&A・提携分析
    Summary Royal Dutch Shell plc (Shell) is an integrated oil and gas company. The company explores for and produces oil and gas from conventional fields and sources such as tight rock, shale and coal formations. Its refining and petrochemical complexes across the world add value to its upstream produc …
  • Globavir Biosciences Inc:医療機器:M&Aディール及び事業提携情報
    Summary Globavir Biosciences Inc (Globavir) is a biotechnology company that develop combination of drug therapies and diagnostic tests in the therapeutic areas of infection and immune-oncology. The company develops Globavir’s Drug Discovery Platform (GDDP), which generates small molecule candidates …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆